Minoryx Therapeutics doses first patient with leriglitazone in registration-enabling cALD NEXUS trial

by Minoryx Therapeutics

Pediatric Investigational Plan (PIP) for leriglitazone in X-ALD approved by EMA, allowing to file Marketing Authorization Application (MAA) in Europe based on NEXUS

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

Iron deficiency is associated with large...

by Vall d’Hebron

The study shows that not only excess but also iron deficiency can have...

Photos Stream